Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 13, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 372 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hemodialysis Patients Clear all
Completed Phase 3 Interventional Results available

Efficacy and Safety of Etelcalcetide (AMG 416) in the Treatment of Secondary Hyperparathyroidism (SHPT) in Patients With Chronic Kidney Disease on Hemodialysis

NCT01785849
View directory record Official record
Conditions
Hyperparathyroidism, Secondary
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 100 Years
Enrollment
508 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2014
U.S. locations
51
States / cities
Birmingham, Alabama • Pine Bluff, Arkansas • Azusa, California + 44 more
Source: ClinicalTrials.gov public record
Updated Aug 26, 2019 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 1 Interventional

A Phase1 Study to Explore the Safety of EOS789 in Patients With Chronic Kidney Disease and Hyperphosphatemia on Hemodialysis

NCT02965053
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
EOS789, Placebo, Renvela
Drug
Lead sponsor
Chugai Pharmaceutical
Industry
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Sep 13, 2018 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 1 Interventional

The Effect of Oral Niacinamide on Serum Phosphorus Levels in Hemodialysis Patients

NCT00316472
View directory record Official record
Conditions
Hyperphosphatemia
Interventions
Niacinamide
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Jan 16, 2009 · Synced Oct 13, 2026, 6:06 PM EDT
Terminated Phase 2 Interventional Results available

An Open-Label, Multiple Dose Study to Evaluate the Pharmacology, Safety, and Tolerability of Patiromer in Participants on Hemodialysis

NCT02033317
View directory record Official record
Conditions
Hyperkalemia
Interventions
patiromer
Drug
Lead sponsor
Relypsa, Inc.
Industry
Eligibility
18 Years to 70 Years
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
2
States / cities
Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated May 12, 2021 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

Continuous Soluble Ferric Pyrophosphate (SFP) Iron Delivery Via Dialysate in Hemodialysis Patients (CRUISE 2)

NCT01322347
View directory record Official record
Conditions
Renal Failure Chronic Requiring Hemodialysis
Interventions
Soluble Ferric Pyrophosphate (SFP), Standard dialysate
Drug · Device
Lead sponsor
Rockwell Medical Technologies, Inc.
Industry
Eligibility
18 Years and older
Enrollment
294 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
38
States / cities
Paragould, Arkansas • Pine Bluff, Arkansas • Alhambra, California + 31 more
Source: ClinicalTrials.gov public record
Updated Apr 26, 2017 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy Study of AB002 (E-WE Thrombin) in End Stage Renal Disease Patients on Chronic Hemodialysis

NCT03963895
View directory record Official record
Conditions
End Stage Renal Disease, Thrombosis
Interventions
AB002 Dose 1, AB002 Dose 2, placebo
Drug
Lead sponsor
Aronora, Inc.
Industry
Eligibility
18 Years to 80 Years
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Mar 7, 2024 · Synced Oct 13, 2026, 6:06 PM EDT
Terminated Phase 3 Interventional

Adenovirus Vascular Endothelial Growth Factor (VEGF) Therapy in Vascular Access - Novel Trinam AGainst Control Evidence

NCT00895479
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
Graft placement surgery plus Trinam therapy
Procedure
Lead sponsor
Ark Therapeutics Ltd
Industry
Eligibility
18 Years and older
Enrollment
250 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2011
U.S. locations
12
States / cities
Long Beach, California • Paducah, Kentucky • Baton Rouge, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Nov 19, 2010 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 4 Interventional

Trial Evaluating the Efficacy of a Chlorhexidine-Impregnated Sponge (BIOPATCH®) to Reduce Catheter-Related Bloodstream Infections in Hemodialysis Patients

NCT00550693
View directory record Official record
Conditions
Catheter Related Bloodstream Infection
Interventions
Chlorhexidine-impregnated foam dressing
Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 85 Years
Enrollment
121 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2005
U.S. locations
2
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Oct 30, 2007 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional

Improving Adherence in Renal Dialysis Patients Through Electronic Interventions

NCT02970201
View directory record Official record
Conditions
Endstage Renal Disease
Interventions
EpxDialysis
Other
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
26 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated May 11, 2018 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

High-Protein Food Snack for Dialysis Patients

NCT04134377
View directory record Official record
Conditions
Renal Failure, Albumin; Double, Diet Habit
Interventions
Protein Food Snack
Other
Lead sponsor
University of Florida
Other
Eligibility
18 Years to 74 Years
Enrollment
52 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Gainesville, Florida
Source: ClinicalTrials.gov public record
Updated Aug 24, 2020 · Synced Oct 13, 2026, 6:06 PM EDT
Not listed Phase 2 Interventional

Efficacy and Tolerability of ILY101 in Dialysis Patients With Hyperphosphatemia

NCT00358046
View directory record Official record
Conditions
Kidney Diseases, Renal Insufficiency
Interventions
ILY101
Drug
Lead sponsor
Ilypsa
Industry
Eligibility
18 Years to 80 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2006
U.S. locations
18
States / cities
Mobile, Alabama • Mountain View, California • Riverside, California + 15 more
Source: ClinicalTrials.gov public record
Updated Feb 7, 2007 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional Results available

Evaluation of Accuracy of Continuous Glucose Monitoring (CGM) in Patients With End Stage Renal Disease (ESRD) on Intermittent Hemodialysis (iHD).

NCT04094064
View directory record Official record
Conditions
Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2
Interventions
Continuous Glucose Monitor
Device
Lead sponsor
University of Virginia
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Charlottesville, Virginia
Source: ClinicalTrials.gov public record
Updated Dec 21, 2022 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 3 Interventional Results available

A Study of Vonapanitase (PRT-201) Administered Immediately After Radiocephalic Arteriovenous Fistula(AVF) Creation in Patients With Chronic Kidney Disease (CKD) (PATENCY-2)

NCT02414841
View directory record Official record
Conditions
Chronic Kidney Disease
Interventions
Vonapanitase, Placebo
Drug
Lead sponsor
Proteon Therapeutics
Industry
Eligibility
18 Years to 100 Years
Enrollment
696 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
36
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 30 more
Source: ClinicalTrials.gov public record
Updated Aug 13, 2019 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional Results available

Trial of Dialysate Sodium in Chronic Hospitalized Hemodialysis Patients

NCT02145260
View directory record Official record
Conditions
Intra-dialytic Hypotension
Interventions
Lower dialysate sodium (138 mmol/L; using Renasol hemodialysis concentrate), Higher dialysate sodium (142 mmol/L; using Renasol hemodialysis concentrate)
Drug
Lead sponsor
Brigham and Women's Hospital
Other
Eligibility
18 Years and older
Enrollment
144 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2021
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 31, 2022 · Synced Oct 13, 2026, 6:06 PM EDT
Terminated Phase 1 Interventional

Dialysate Sodium Individualization in Hemodialysis

NCT00259714
View directory record Official record
Conditions
Hypertension, Hemodialysis Patients
Interventions
dialysate sodium individualization, standard dialysate sodium
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years to 90 Years
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 22, 2016 · Synced Oct 13, 2026, 6:06 PM EDT
Completed No phase listed Observational

Patient Activation in Dialysis

NCT04066140
View directory record Official record
Conditions
Renal Dialysis, Kidney Failure, Chronic
Interventions
No intervention
Other
Lead sponsor
Satellite Healthcare
Other
Eligibility
18 Years and older
Enrollment
227 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
36
States / cities
Daly City, California • Los Gatos, California • Merced, California + 23 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2020 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of LY3113593 in Healthy Participants and Participants With Chronic Kidney Disease Treated With Hemodialysis

NCT02144285
View directory record Official record
Conditions
Kidney Failure, Chronic
Interventions
LY3113593, Placebo
Drug
Lead sponsor
Eli Lilly and Company
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014 – 2015
U.S. locations
3
States / cities
Glendale, California • Orlando, Florida • Minneapolis, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 22, 2019 · Synced Oct 13, 2026, 6:06 PM EDT
Terminated Not applicable Interventional Results available

Evaluation of Anti-platelet Factor 4/Heparin Antibodies in Hemodialysis Patients

NCT02165761
View directory record Official record
Conditions
End Stage Renal Disease
Interventions
GORE® Hybrid Vascular Graft, Non-heparin bonded synthetic graft
Device
Lead sponsor
W.L.Gore & Associates
Industry
Eligibility
18 Years and older
Enrollment
42 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2017
U.S. locations
4
States / cities
Hackensack, New Jersey • Charlotte, North Carolina • Durham, North Carolina + 1 more
Source: ClinicalTrials.gov public record
Updated Feb 19, 2018 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional

A Study to Demonstrate the Safety and Effectiveness of the NIKKISO DBB-EXA ES Hemodialysis Delivery System

NCT04655989
View directory record Official record
Conditions
Dialysis, Chronic Renal Failure
Interventions
DBB-EXA ES Hemodialysis System
Device
Lead sponsor
Nikkiso America, Inc.
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
2
States / cities
Detroit, Michigan • Southfield, Michigan
Source: ClinicalTrials.gov public record
Updated Oct 6, 2021 · Synced Oct 13, 2026, 6:06 PM EDT
Terminated No phase listed Observational

Cognitive and Functional Status and Dialysis Outcomes in Older Hemodialysis Patients

NCT00739843
View directory record Official record
Conditions
Dementia, Cognition, End-stage Renal Disease
Interventions
Not listed
Lead sponsor
University of Chicago
Other
Eligibility
60 Years and older
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated Nov 1, 2016 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

Pharmacokinetics of JULUCA in Hemodialysis

NCT04431518
View directory record Official record
Conditions
HIV/AIDS, ESRD
Interventions
JULUCA 50Mg-25Mg Tablet
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 65 Years
Enrollment
8 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 5, 2024 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Not applicable Interventional Results available

A Study to Assess the Tolerability and Efficacy of AKST1210 in Patients on Hemodialysis With Cognitive Impairment

NCT04527328
View directory record Official record
Conditions
Cognitive Impairment, End Stage Renal Disease
Interventions
AKST1210, Sham Control (No Intervention), Hemodialysis
Device · Other · Procedure
Lead sponsor
Alkahest, Inc.
Industry
Eligibility
40 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
4
States / cities
Granada Hills, California • Northridge, California • Orlando, Florida + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 12, 2022 · Synced Oct 13, 2026, 6:06 PM EDT
Completed No phase listed Observational

Anxiety and Symptom Burden in Hemodialysis Patients

NCT04143100
View directory record Official record
Conditions
Anxiety, ESRD
Interventions
Survey
Other
Lead sponsor
The Rogosin Institute
Other
Eligibility
18 Years and older
Enrollment
100 participants
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 2, 2022 · Synced Oct 13, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Safety, Tolerability and Efficacy of Etelcalcetide in Hemodialysis Patients With Secondary Hyperparathyroidism

NCT01254565
View directory record Official record
Conditions
Secondary Hyperparathyroidism
Interventions
Etelcalcetide, Placebo
Drug
Lead sponsor
KAI Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
87 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
13
States / cities
Azusa, California • Costa Mesa, California • Lynwood, California + 9 more
Source: ClinicalTrials.gov public record
Updated Apr 13, 2017 · Synced Oct 13, 2026, 6:06 PM EDT